- Exchange: NASDAQ CM
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Keryx Biopharmaceuticals Inc
+ Add to WatchlistKERX:US
8.0300 USD 0.1500 1.90%As of 20:10:00 ET on 05/23/2013.
Company Profile for Keryx Biopharmaceuticals Inc (KERX)
Keryx Biopharmaceuticals, Inc. is focused on developing and commercializing pharmaceuticals for the treatment of renal disease. The Company's product candidate completed Phase 3 testing, pursuant to an SPA agreement with the FDA, for hyperphosphatemia in ESRD patients. The product candidate is also in Phase 2 for non-dialysis dependent CKD patients with iron-deficiency anemia.
Contact Information
Keryx Biopharmaceuticals Inc
750 Lexington Avenue
New York, NY 10022
United States
Key Executives for Keryx Biopharmaceuticals Inc (KERX)
| Ron BentsurChief Executive Officer | James F OlivieroCFO/Treasurer/Secretary |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Rate this Page